EMERGENT BIOSOLUTIONS INC. Fair Value Adjustment of Warrants
EMERGENT BIOSOLUTIONS INC. (EBS) reported Fair Value Adjustment of Warrants of -$8.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$500.00K, a 117.24% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$8.40M.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $7.30M, a 231.82% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was $4.80M.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for fiscal 2025 was $5.50M, a 400.00% increase from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for fiscal 2024 was $1.10M.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for fiscal 2023 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value adjustment of warrants for fiscal 2022 was $0.00.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.90M 10-Q · filed 2026-08-06 | -$1.60M derived: sum of 3 quarters · filed 2026-08-06 | $3.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$8.40M 10-Q · filed 2026-05-01 | -$1.10M derived: sum of 2 quarters · filed 2026-05-01 | $3.70M derived: sum of 3 quarters · filed 2026-05-01 | $6.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.10M derived: sum of 2 quarters · filed 2026-02-27 | $15.00M derived: sum of 3 quarters · filed 2026-08-06 | $5.50M 10-K · filed 2026-02-27 |
| 2025-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $7.70M derived: sum of 2 quarters · filed 2026-08-06 | -$1.80M 10-Q · filed 2025-10-30 | $400.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.60M 10-Q · filed 2026-08-06 | -$4.40M derived: sum of 3 quarters · filed 2026-08-06 | -$5.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.50M 10-Q · filed 2026-05-01 | -$7.30M derived: sum of 2 quarters · filed 2026-05-01 | -$8.40M derived: sum of 3 quarters · filed 2026-05-01 | -$8.40M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.10M derived: sum of 2 quarters · filed 2026-02-27 | $1.10M derived: sum of 3 quarters · filed 2026-02-27 | $1.10M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.10M derived: sum of 2 quarters · filed 2025-10-30 | -$1.10M 10-Q · filed 2025-10-30 | -$1.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |